查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2134973

全球中風治療產品線分析 - 2026 年（第二季洞察與臨床試驗）

Global Stroke Drug Pipeline Analysis, 2026 (Q2 Insights & Clinical Trials)
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 151 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

製藥和生物技術公司正在積極開發新型溶栓劑、神經保護劑、抗發炎療法、再生醫學和聯合治療，以滿足急性中風治療和長期康復方面尚未滿足的關鍵需求。

中風仍然是全球主要的死亡和長期殘疾原因之一，而藥物研發的重點主要集中在缺血性中風領域。儘管溶栓療法和機械取栓術已顯著改善了臨床療效，但仍有許多患者不符合現有治療條件，或持續遭受永久性神經功能障礙的困擾。本報告的藥物研發管線分析全面深入地探討了在臨床實驗療法、臨床開發階段、作用機制、申辦方活動、監管趨勢、競爭格局以及商業化機遇，這些都將影響中風治療的未來發展方向。

市場促進因素

全球中風負擔日益加重。

  • 由於老化、高血壓、糖尿病、肥胖、心房顫動和其他心血管危險因子導致中風發病率不斷上升，對創新療法的需求持續成長。中風帶來的巨大醫療和經濟負擔，推動了藥物研發和臨床開發領域的持續投入。

下一代再灌注療法的擴展

  • 臨床上對改善再灌注治療效果的日益關注，正在加速研發新一代溶栓藥物，這些藥物旨在簡化給藥方式、加速治療速度並擴大適用患者群體。近期監管方面的進展進一步加強了對該治療領域的投資。

人們越來越關注神經保護

  • 製藥公司正在加強對神經保護療法的研究力度，旨在保護神經組織，並在缺血性損傷後改善長期功能恢復。這些療法是其研發管線中最具前景的創新領域之一。

影像導引治療的進展

  • 神經影像技術的進步使得患者選擇更加精準，治療時間得以延長，促使贊助公司積極開發與影像引導中風管理策略相輔相成的療法。

市場限制因素

臨床試驗失敗率高

  • 由於中風的生物機制複雜、患者群體異質性以及難以證明一致的臨床療效，神經保護藥物的研發歷來面臨較高的停藥率。

複雜的臨床開發

  • 開發卒中治療方案需要快速招募患者、制定標準化的影像學檢查方案、大規模多中心試驗以及對神經系統預後進行長期評估。臨床試驗成本高昂，且會帶來沉重的營運負擔。

監管挑戰

  • 監管機構正在尋求強力的證據，以證明在維持可接受的安全狀況（特別是與再灌注治療相關的出血風險）的同時，功能恢復方面有顯著改善。

深入了解管道和技術

  • 全球中風治療藥物研發管線可依研發階段、中風類型、藥物類型、治療方法、作用機制及地區分類。
  • 從研發階段來看，在研藥物包括臨床前、I期、II期、III期以及已提交/正在接受監管審查的候選藥物。 II期和III期計畫佔在研藥物總數的最大比例，因為申辦者正致力於推動有前景的療法走向商業化。
  • 從中風類型來看，研發管線涵蓋缺血性中風、出血性中風、短暫性腦缺血發作（TIA）和其他腦血管疾病。缺血性中風佔中風病例的大多數，也是治療創新潛力最大的領域，因此是研發的重點。
  • 從藥物類別來看，在研藥物包括溶栓藥物、抗血小板藥物、抗凝血藥物、神經保護藥物、抗發炎療法、再生醫學藥物等在臨床實驗藥物類別。溶栓藥物仍然是研發最活躍的類別，但隨著申辦者尋求互補的治療方法，神經保護療法和再生醫學藥物也不斷發展。
  • 從治療類型來看，在研療法包括靜脈注射藥物、血管內治療和外科切除術。製藥公司正日益尋求能夠補充現有介入治療並改善功能性預後的療法。
  • 技術創新不斷推動研發管線的進展，包括人工智慧 (AI) 驅動的影像診斷、基於生物標記的患者選擇、精準醫療、適應性臨床試驗設計以及簡化試驗和最佳化治療的數位健康平台。

管道趨勢

  • 全球中風治療方案不斷發展，納入了標靶治療和聯合治療等治療策略。

主要趨勢如下：

  • 擴大下一代溶栓藥物的研發。
  • 加大對神經保護療法的投資。
  • 包含血栓切除術在內的聯合治療正在不斷發展。
  • 基於影像診斷的患者選擇方法已被廣泛應用。
  • 擴大再生醫學和神經功能恢復計畫。
  • 採用適應性臨床試驗設計的方法越來越多。
  • 加強延長治療窗口期。

區域趨勢

  • 北美憑藉其先進的臨床研究基礎設施、強力的監管支持、廣泛的學術合作以及大量的製藥投資，仍然是中風治療藥物研發領域的領先地區。美國在藥物商業化和後期臨床開發方面繼續發揮主導作用。
  • 歐洲憑藉其跨國臨床研究網路、完善的卒中治療體係以及積極參與全球藥物研發項目，保持強大的市場地位。影像引導治療策略持續推動著全部區域的創新發展。
  • 受中國、日本、韓國、印度和澳洲中風盛行率上升、臨床試驗能力擴大、醫療保健基礎設施改善以及製藥投資增加等因素的推動，亞太地區有望成為中風治療發展領域成長最快的地區之一。
  • 拉丁美洲、中東和非洲正透過醫療保健現代化、擴大中風治療能力以及加強與國際製藥公司的合作，逐步增加其參與跨國臨床研究的程度。

競爭格局

  • 全球中風治療產品線涵蓋跨國製藥公司、生技公司、學術研究機構和新興生物技術開發公司。
  • 領先企業持續投資新一代溶栓藥物、神經保護劑、再生醫學、抗發炎療法、精準醫療和聯合療法策略。戰略許可協議、合作研究夥伴關係、併購以及監管部門的快速核准程序仍然是企業保持競爭優勢的關鍵。基因泰克、勃林格殷格翰、羅氏、諾華、拜耳、強生、第一三共和賽諾菲等公司正積極致力於加強其中風治療藥物的研發組合。

未來展望

  • 中風治療的未來發展將受到精準神經病學、人工智慧、再生醫學、影像引導治療和個人化醫療等領域持續進步的影響。神經保護策略的拓展、對中風病理生理學的深入理解以及數位健康技術的更廣泛應用，有望加速創新療法的研發。
  • 到 2035 年，適應性臨床試驗設計、基於生物標記的開發和聯合療法的日益普及將提高開發效率並創造新的商業性機會。

結論

  • 這份「全球中風治療產品線分析」報告重點介紹了快速發展的研發格局，其驅動力包括神經學研究投入的增加、溶栓療法的創新、神經保護技術的進步以及對改善長期功能恢復日益成長的關注。儘管臨床複雜性、監管要求和先前失敗率等挑戰依然存在，但精準醫療、影像技術和聯合治療策略的持續進步有望加速創新，並提升未來的商業化機會。

本報告的主要益處

  • 對全球中風治療產品線所有研發階段進行全面分析。
  • 在臨床實驗期間對治療方法、作用機制和研發管線成熟度進行詳細評估。
  • 對贊助商活動、策略聯盟和授權趨勢進行競爭分析。
  • 洞察監管趨勢、新興技術和商業化機會。
  • 這將是製藥公司、生物技術公司、合約研究組織 (CRO)、醫療保健提供者、投資者、顧問和政策制定者的重要資訊來源。

我們報告的用途

  • 產品線基準分析、產品組合最佳化、競爭情報分析、許可和合作評估、臨床開發規劃、投資分析、監管策略制定、商業化規劃和長期策略決策。

調查範圍

  • 歷史資料涵蓋 2021 年至 2025 年，基準年為 2025 年，預測期間為 2026 年至 2035 年。
  • 全球中風治療產品線進行全面分析，並依研發階段、中風類型、藥物類型、治療方法及地區細分。
  • 針對在研產品、臨床開發進展、作用機制、申辦者趨勢、監管管道及商業化潛力進行評估。
  • 對策略聯盟、授權協議、併購、競爭格局和新興治療創新進行評估。
  • 對溶栓劑、神經保護療法、再生醫學、抗血小板藥物、抗凝血劑、聯合治療以及 2035 年的未來研發機會進行分析。

目錄

第1章：引言

  • 調查方法
  • 調查範圍
    • 分析：按公司
    • 分析：按發展階段
    • 分析：按干預類型分類
    • 分析：按臨床試驗狀態
    • 分析：按地區
  • 數據來源和檢驗
  • 定義和假設

第2章 疾病概述

  • 疾病分類
  • 病因和風險因素
  • 症狀和臨床觀察
  • 診斷
  • 目前治療狀況
  • 流行病學和疾病負擔
  • 未滿足的臨床需求

第3章執行摘要

  • 臨床階段產品線概覽
  • 按開發階段分類的管道分佈
  • 臨床試驗活動中的主要公司
  • 主要臨床實驗藥物和療法
  • 各地區臨床試驗現狀
  • 管道構建中的關鍵趨勢和發現

第4章：中風管道的動力學

  • 因素
  • 限制
  • 管道利用機會

第5章 管道分析/預測

  • 管道分析：按公司分類
    • Genentech
    • Boehringer Ingelheim
    • F. Hoffmann-La Roche
    • Novartis
  • 管線分析：依開發階段分類
    • 第一階段
    • 第一階段
    • 第一/二期
    • 第二階段
    • 第二/三期
    • 第三階段
  • 管道分析：依干預類型分類
    • 製藥
    • 生物
    • 基因
  • 產品線分析：依疾病/患者群分類
    • 缺血性中風
    • 出血性中風
    • 中風後復健/二級預防
  • 管線分析：依臨床試驗進展
    • 我們尚未開始招募參與者。
    • 招募測試對象
    • 目前已暫停招募參與者。
    • 完成
    • 取消/撤回/暫停
  • 管道分析：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 臨床試驗和病患分析
    • 按註冊患者人數統計的臨床試驗
    • 依研究設計進行的臨床試驗
    • 患者年齡要求
    • 關於患者性別的合格標準
  • 贊助和合作關係分析
    • 主要商業贊助商
    • 主要學術和研究贊助商
    • 主要合作夥伴組織
    • 贊助商和合作研究者分析
  • 近期和未來管道趨勢
    • 近期啟動的臨床試驗
    • 目前正在招募參與者的臨床試驗
    • 近期完成的臨床試驗
    • 後期臨床試驗即將完成
    • 近期已發表結果的臨床試驗

第6章：公司簡介

  • Genentech
  • Boehringer Ingelheim
  • F. Hoffmann-La Roche
  • Novartis

第7章 圖表清單

第8章：圖表清單

簡介目錄
Product Code: KSI-008955

Pharmaceutical and biotechnology companies are actively advancing novel thrombolytics, neuroprotective agents, anti-inflammatory therapies, regenerative medicines, and combination approaches to address the significant unmet clinical needs in acute stroke management and long-term recovery.

Stroke remains one of the leading causes of death and long-term disability worldwide, with ischemic stroke representing the primary focus of pipeline development. Although thrombolysis and mechanical thrombectomy have significantly improved clinical outcomes, many patients remain ineligible for current interventions or continue to experience permanent neurological impairment. Drug pipeline analysis provides comprehensive insights into investigational therapies, clinical development stages, mechanisms of action, sponsor activities, regulatory trends, competitive positioning, and commercialization opportunities that are shaping the future stroke treatment landscape.

Market Drivers

Growing Global Stroke Burden

  • The increasing incidence of stroke resulting from aging populations, hypertension, diabetes, obesity, atrial fibrillation, and other cardiovascular risk factors continues to accelerate demand for innovative therapeutic options. The substantial healthcare and economic burden associated with stroke is encouraging sustained investment in drug discovery and clinical development.

Expansion of Next-Generation Reperfusion Therapies

  • Growing clinical interest in improving reperfusion outcomes has accelerated development of next-generation thrombolytic agents that offer simplified administration, faster treatment, and broader patient eligibility. Recent regulatory advances have further strengthened investment in this therapeutic area.

Increasing Focus on Neuroprotection

  • Pharmaceutical companies are expanding research into neuroprotective therapies designed to preserve neuronal tissue during ischemic injury and improve long-term functional recovery. These therapies represent one of the most promising areas of pipeline innovation.

Advances in Imaging-Guided Treatment

  • Improved neuroimaging technologies are enabling more precise patient selection and extending treatment windows, encouraging sponsors to develop therapies that complement imaging-guided stroke management strategies.

Market Restraints

High Clinical Failure Rates

  • Neuroprotective drug development has historically experienced high attrition rates because of complex stroke biology, heterogeneous patient populations, and difficulties in demonstrating consistent clinical benefit.

Complex Clinical Development

  • Stroke drug development requires rapid patient enrollment, standardized imaging protocols, large multicenter studies, and long-term neurological outcome assessment, making clinical trials expensive and operationally demanding.

Regulatory Challenges

  • Regulatory agencies require robust evidence demonstrating meaningful improvements in functional recovery while maintaining acceptable safety profiles, particularly regarding bleeding risk associated with reperfusion therapies.

Pipeline and Technology Insights

  • The global stroke drug pipeline can be segmented by development phase, stroke type, drug type, treatment type, mechanism of action, and geography.
  • By development phase, the pipeline includes preclinical, Phase I, Phase II, Phase III, and filed/under regulatory review candidates. Phase II and Phase III programs represent the largest share of active development as sponsors advance promising therapies toward commercialization.
  • By stroke type, pipeline activity covers ischemic stroke, hemorrhagic stroke, transient ischemic attack (TIA), and other cerebrovascular disorders. Ischemic stroke dominates development because it represents the majority of stroke cases and offers the greatest opportunity for therapeutic innovation.
  • By drug type, the pipeline includes thrombolytics, antiplatelets, anticoagulants, neuroprotective agents, anti-inflammatory therapies, regenerative therapies, and other investigational drug classes. Thrombolytics remain the most active development category, while neuroprotective and regenerative therapies continue to expand as sponsors pursue complementary treatment approaches.
  • By treatment type, pipeline assets include intravenous medications, endovascular therapies, and surgical procedures, including mechanical thrombectomy and carotid endarterectomy. Drug developers increasingly seek therapies that complement existing interventional procedures and improve functional outcomes.
  • Technological innovation continues to support pipeline advancement through artificial intelligence-assisted imaging, biomarker-guided patient selection, precision medicine, adaptive clinical trial designs, and digital health platforms that improve trial efficiency and treatment optimization.

Pipeline Trends

  • The global stroke drug pipeline continues to evolve toward targeted and combination therapeutic strategies.

Key trends include:

  • Expansion of next-generation thrombolytic development.
  • Increasing investment in neuroprotective therapies.
  • Growing development of combination therapies with thrombectomy.
  • Broader use of imaging-guided patient selection.
  • Expansion of regenerative medicine and neurological recovery programs.
  • Increasing adoption of adaptive clinical trial designs.
  • Greater focus on extending treatment eligibility windows.

Regional Insights

  • North America remains the leading region for stroke drug pipeline development because of advanced clinical research infrastructure, strong regulatory support, extensive academic collaboration, and substantial pharmaceutical investment. The United States continues to lead commercialization and late-stage clinical development.
  • Europe maintains a strong position through multinational clinical research networks, established stroke care systems, and active participation in global drug development programs. Imaging-guided treatment strategies continue to drive innovation across the region.
  • Asia-Pacific is expected to emerge as one of the fastest-growing regions for stroke drug development owing to increasing stroke prevalence, expanding clinical trial capabilities, improving healthcare infrastructure, and growing pharmaceutical investment across China, Japan, South Korea, India, and Australia.
  • Latin America and the Middle East & Africa are gradually strengthening their participation in multinational clinical research through healthcare modernization, expanding stroke treatment capacity, and increasing collaboration with international pharmaceutical companies.

Competitive Landscape

  • The global stroke drug pipeline includes multinational pharmaceutical companies, biotechnology firms, academic research institutions, and emerging biotechnology developers.
  • Leading organizations continue investing in next-generation thrombolytics, neuroprotective agents, regenerative medicine, anti-inflammatory therapies, precision medicine, and combination treatment strategies. Strategic licensing agreements, collaborative research partnerships, mergers and acquisitions, and regulatory acceleration programs remain central to competitive growth. Companies including Genentech, Boehringer Ingelheim, Roche, Novartis, Bayer, Johnson & Johnson, Daiichi Sankyo, and Sanofi are actively strengthening their stroke development portfolios.

Future Outlook

  • The future of the stroke drug pipeline will be shaped by continued advances in precision neurology, artificial intelligence, regenerative medicine, imaging-guided treatment, and personalized therapeutics. Expansion of neuroprotective strategies, improved understanding of stroke pathophysiology, and broader integration of digital health technologies are expected to accelerate development of innovative therapies.
  • Increasing adoption of adaptive trial designs, biomarker-guided development, and combination treatment approaches will improve development efficiency while creating new commercial opportunities through 2035.

Conclusion

  • The global Stroke Drug Pipeline Analysis highlights a rapidly expanding development landscape supported by growing neurological research investment, innovation in thrombolytic therapies, advances in neuroprotection, and increasing emphasis on improving long-term functional recovery. Although challenges related to clinical complexity, regulatory requirements, and historical failure rates remain, continued advances in precision medicine, imaging technologies, and combination therapeutic strategies are expected to accelerate innovation and strengthen future commercialization opportunities.

Key Benefits of this Report

  • Comprehensive analysis of the global stroke drug pipeline across all stages of development.
  • Detailed evaluation of investigational therapies, mechanisms of action, and pipeline maturity.
  • Competitive assessment of sponsor activities, strategic collaborations, and licensing trends.
  • Insights into regulatory developments, emerging technologies, and commercialization opportunities.
  • Valuable resource for pharmaceutical companies, biotechnology firms, contract research organizations, healthcare providers, investors, consultants, and policymakers.

What Businesses Use Our Reports For

  • Pipeline benchmarking, portfolio optimization, competitive intelligence, licensing and partnership evaluation, clinical development planning, investment analysis, regulatory strategy development, commercialization planning, and long-term strategic decision-making.

Report Coverage

  • Historical data from 2021 to 2025, Base Year 2025, and Forecast Period 2026 to 2035
  • Comprehensive analysis of the global stroke drug pipeline by development phase, stroke type, drug type, treatment type, and geography
  • Evaluation of pipeline assets, clinical development progress, mechanisms of action, sponsor landscape, regulatory pathways, and commercialization potential
  • Assessment of strategic collaborations, licensing agreements, mergers and acquisitions, competitive positioning, and emerging therapeutic innovations
  • Analysis of thrombolytics, neuroprotective therapies, regenerative medicine, antiplatelets, anticoagulants, combination therapies, and future pipeline opportunities through 2035.

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Research Methodology
  • 1.2. Research Scope
    • 1.2.1. Analysis by Company
    • 1.2.2. Analysis by Development Phase
    • 1.2.3. Analysis by Intervention Type
    • 1.2.4. Analysis by Clinical Trial Status
    • 1.2.5. Analysis by Geography
  • 1.3. Data Sources and Validation
  • 1.4. Definitions and Assumptions

2. DISEASE OVERVIEW

  • 2.1. Introduction
  • 2.2. Disease Classification
  • 2.3. Causes and Risk Factors
  • 2.4. Symptoms and Clinical Manifestations
  • 2.5. Diagnosis
  • 2.6. Current Treatment Landscape
  • 2.7. Epidemiology and Disease Burden
  • 2.8. Unmet Clinical Needs

3. EXECUTIVE SUMMARY

  • 3.1. Clinical-Stage Pipeline Overview
  • 3.2. Pipeline Distribution by Development Phase
  • 3.3. Leading Companies by Clinical Trial Activity
  • 3.4. Leading Investigational Drugs and Interventions
  • 3.5. Geographic Clinical Trial Landscape
  • 3.6. Key Pipeline Trends and Findings

4. STROKE PIPELINE DYNAMICS

  • 4.1. Drivers
  • 4.2. Restraints
  • 4.3. Pipeline Opportunities

5. PIPELINE ANALYSIS / OUTLOOK

  • 5.1. PIPELINE ANALYSIS BY COMPANY
    • 5.1.1. Genentech
    • 5.1.2. Boehringer Ingelheim
    • 5.1.3. F. Hoffmann-La Roche
    • 5.1.4. Novartis
  • 5.2. PIPELINE ANALYSIS BY DEVELOPMENT PHASE
    • 5.2.1. Early Phase I
    • 5.2.2. Phase I
    • 5.2.3. Phase I/II
    • 5.2.4. Phase II
    • 5.2.5. Phase II/III
    • 5.2.6. Phase III
  • 5.3. PIPELINE ANALYSIS BY INTERVENTION TYPE
    • 5.3.1. Drug
    • 5.3.2. Biological
    • 5.3.3. Genetic
  • 5.4. PIPELINE ANALYSIS BY DISEASE / PATIENT SEGMENT
    • 5.4.1. Ischemic Stroke
    • 5.4.2. Hemorrhagic Stroke
    • 5.4.3. Post-Stroke Recovery / Secondary Prevention
  • 5.5. PIPELINE ANALYSIS BY CLINICAL TRIAL STATUS
    • 5.5.1. Not Yet Recruiting
    • 5.5.2. Recruiting
    • 5.5.3. Active, Not Recruiting
    • 5.5.4. Completed
    • 5.5.5. Terminated / Withdrawn / Suspended
  • 5.6. PIPELINE ANALYSIS BY GEOGRAPHY
    • 5.6.1. North America
    • 5.6.2. Europe
    • 5.6.3. Asia-Pacific
    • 5.6.4. Latin America
    • 5.6.5. Middle East & Africa
  • 5.7. CLINICAL TRIAL AND PATIENT ANALYSIS
    • 5.7.1. Clinical Trials by Patient Enrollment
    • 5.7.2. Clinical Trials by Study Design
    • 5.7.3. Patient Age Eligibility
    • 5.7.4. Patient Sex Eligibility
  • 5.8. SPONSOR AND COLLABORATION ANALYSIS
    • 5.8.1. Leading Commercial Sponsors
    • 5.8.2. Leading Academic and Research Sponsors
    • 5.8.3. Leading Collaborating Organizations
    • 5.8.4. Sponsor-Collaborator Analysis
  • 5.9. RECENT AND UPCOMING PIPELINE ACTIVITY
    • 5.9.1. Recently Initiated Clinical Trials
    • 5.9.2. Newly Recruiting Clinical Trials
    • 5.9.3. Recently Completed Clinical Trials
    • 5.9.4. Late-Stage Trials Approaching Primary Completion
    • 5.9.5. Trials with Recently Posted Results

6. COMPANY PROFILES

  • 6.1. Genentech
  • 6.2. Boehringer Ingelheim
  • 6.3. F. Hoffmann-La Roche
  • 6.4. Novartis

7. LIST OF TABLES

8. LIST OF FIGURES